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Phenotypic biomarkersMitochondria aremultifunctional organelles that play a central role in cellular homeostasis. Severemitochondrial
dysfunction leads to life-threatening diseases in humans and accelerates the aging process. Surprisingly,moderate
reduction of mitochondrial function in different species has anti-aging effects. High-throughput screenings in the
nematode Caenorhabditis elegans lead to the identiﬁcation of several pro-longevity genetic and pharmacological
interventions. Large-scale screens, however, are manual, subjective, time consuming and costly. These limitations
could be reduced by the identiﬁcation of automatically quantiﬁable biomarkers of healthy aging. In this study we
exploit the distinct and reproducible phenotypes described in C. elegans upon different levels of mitochondrial
alteration to develop an automated high-content strategy to identify new potential pro-longevity interventions.
Utilizing the microscopy platform Cellomics ArrayScan Reader, we optimize a workﬂow to automatically and
reliably quantify the discrete phenotypic readouts associated with different degrees of silencing of mitochondrial
respiratory chain regulatory proteins, and validate the approach with mitochondrial-targeting drugs known to
extend lifespan inC. elegans. Finally,we report that a newmitochondrial ATPasemodulatormatches our screening
phenotypic criteria and extends nematode's lifespan thus providing the proof of principle that our strategy could
be exploited to identify novel mitochondrial-targeted drugs with pro-longevity activity. This article is part of a
Special Issue entitled: Mitochondrial Dysfunction in Aging.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Drug screenings in search of enhancers or suppressors of selected
readout(s) are conventionally carried out in single cell systems and can
be classiﬁed in two main categories: high-throughput screening (HTS)
and high-content screening (HCS). HTS uses robotics, data processing
and control softwares, liquid handling devices, and sensitive detectors,
to allow quick tests of a large number of agents. HTS is characterized
by low cost, simplicity, rapidness and high efﬁciency [1]. HCS is an auto-
mated microscope-based screen that concurrently measures multiple
features following treatments with the interventions under study. In
contrast to HTS, which often has a single readout of activity, HCS allows
for the measurement of many properties at once [2]. Both types of
screenings are relatively easy to employ with mammalian tissue culturendrial Dysfunction in Aging.
istry and Laboratory Diagnostic,
IUF—Leibniz Research Institute
40225 Düsseldorf, Germany.
N. Ventura).cells, bacteria and yeast. Moreover, in the past decade, invertebrate
animals have been used as model organisms to more closely mimic dis-
ease states and timing development ofmulticellular organisms [3].Many
diseases, indeed, affect organs as awhole, and sometimesmore than one
organ. Although in some cases, organs can be reconstituted in vitro, for
most cases (e.g. neuromuscular disorders) this is still not possible. More-
over cells, tissues and organs are interconnected at different levels (e.g.
physically through direct contacts or vases, or physiologically through
hormones or cytokines), and their interaction, which in most cases is
critical for disease development and progression, is better recapitulated
in in vivomodel organisms. Finally, the timing of disease development
and progression can rarely be represented in in vitro single cells systems.
The advantages of using multicellular organisms become evenmore ob-
vious when searching for interventions with potential anti-aging effects
since aging is speciﬁcally associated with a progressive systemic deteri-
oration in multiple tissues, organs, and physiological functions.
The nematode Caenorhabditis elegans (C. elegans) is a versatile
platform for whole-organism screening purposes due to a unique com-
bination of features. These include its cell lineage, which is known and
invariant, its genome, which is completely sequenced and shares a high
homologywith the human [4], and its inexpensive and simple cultivation
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body is optically transparent, enabling easy observation of cells with
orwithout the aid of ﬂuorescent gene expression or use of dyes, a feature
which has proven useful for the development of in vivo high-throughput
and, more recently, high-content screenings [5–13]. The instrumental
role of C. elegans as a powerful model organism to study aging is
underscored by the fact that different age-associated features described
in mammals (e.g. neuromuscular deterioration, decline in physiological
function, and resistance to stress) are recapitulated during C. elegans
aging [14] and by the fact that genome wide-screenings have been
used to identify genes and pathways regulating longevity [15,16]. More-
over, the discovery of dietary and pharmacological factors that can delay
adverse, age-associated changes has recently stimulated the use of high-
throughput screenings in C. elegans to identify compounds or small mol-
ecules extending lifespan [17–19]. These large-scale screens are however
manual and subjective and only two automated platforms, based on
microﬂuidic devices, have been developed to identify lifespan-
modulating interventions inC. elegans [20–22]. These approaches remain
nonetheless time consuming and costly due to the time that is necessary
to assess lifespan, a limitation that in principle could be reduced by the
identiﬁcation of automatically quantiﬁable biomarkers of healthy aging.
The goal of this study was to identify early surrogate readouts for
healthy aging that can be used to develop high-content screenings. To
this end, we exploited the highly reproducible phenotypic changes
associated with different levels of mitochondrial stress [23,24] (Fig. 1),
which represent ideal parameters for automated microscopy quantiﬁ-
cation (e.g. animal size, induction of ﬂuorescent transgenes). We
utilized the Cellomics Arrayscan VTI HCS Reader platform,which similarFig. 1. Different degrees of mitochondrial stress lead in C. elegans to different phenoty
mild RNAi-mediated suppression of proteins regulatingmitochondrial functionality) showa red
than wild-type (control) animals. On the contrary, strong RNAi against the same genes lead toto other microscopy platforms, combines automated bright-ﬁeld and
ﬂuorescence images acquisition with real-time quantiﬁcation and
analysis of multiple parameters such as size, shape, ﬂuorescence in-
tensity and distribution. This platform was successfully adapted to
C. elegans by Gosai and coworkers to screen and identify small mole-
cules affecting the aggregation of the serpin α1-antitrypsin-Z that
causes disease in humans [10]. First, we optimized image acquisition
and analysis using the Cellomics SpotDetector BioApplication in an-
imals with different levels of suppression of mitochondrial proteins.
We then validated the platform by assessing phenotypic changes in-
duced by classical mitochondrial-targeting drugs with demonstrated
life-extending effects in C. elegans, and found that, consistently, they
reduced animal size at the low, life-extending concentration, while
arresting animal development at higher doses. Finally, we assessed
whether modulators of the mitochondrial F1F0-ATPase, with thera-
peutic properties in murine models of autoimmune disease [25],
could ﬁt our phenotypic criteria and possibly extend C. elegans lifespan.
We provided proof-of-principle that phenotypic criteria can predict
C. elegans lifespan and can be thus exploited for a high-content screen-
ing strategy aimed at the identiﬁcation of compounds or small mole-
cules that promote life-extension by targeting mitochondria.
2. Results
2.1. High-content phenotypic-based screening platform setup
Different levels of mitochondrial stress in C. elegans lead to distinct
and reproducible phenotypic outcomes [23,24,26–28]. Namely, severepic readouts. Animals with a mild reduction of mitochondrial functionality (through
uction in body size and daily fecundity, are long-lived and healthier (highlighted in green)
developmental arrest and/or shortening of lifespan (highlighted in red).
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pathological phenotypes, such as arrested animal development and/or
shortened lifespan, similar to that in humans. Instead, moderate
suppression of the same proteins extends lifespan, and is associated
with reduced animals size and daily fertility (Fig. 1). The underlying
molecular mechanisms of mitochondrial stress extension of lifespan
are the subject of active investigation and remain to be fully eluci-
dated [29,30]. Nonetheless, considering the evolutionarily con-
served nature of this paradoxical phenomenon [31,32] and the
critical role of mitochondria in the aging process [33,34], pharmaco-
logical manipulation of mitochondria is an appealing strategy to pro-
long healthy aging. To this end we exploited the phenotypic and
biochemical changes typically associated with extended C. elegans
healthy aging upon mild mitochondrial stress [35], i.e. smaller
adult size and induction of stress response genes [36], as early surro-
gate markers for lifespan extension to establish a phenotypic-based
screening. Speciﬁcally, we optimized automated microscopy proto-
cols to quantify discrete animals' amount, size, and transgene ex-
pression, utilizing the SpotDetector, one of the Bio Applications of
the Cellomic ArrayScan Reader imaging platform.
As a ﬁrst step we established the maximum number of animals
the SpotDetector could recognize as valid objects in a 96-well plate
(Fig. 2A). The SpotDetector was set up to reject objects (animals) that
touch each other, otherwise recognized as giant objects in the next
phase, or that touch the wall of the well, which would possibly be
otherwise recognized as a valid object. Hence the higher the number
or size of the objects, the higher the probability is that they touch
each other and are excluded from the count. We established that theFig. 2. Optimized protocols for objects number and size. A)Representative bright-ﬁeld picture
well shown as example (left side) all the animals identiﬁed as objects are labeled in blue, whi
On the right side the 96-well under scan is shown, with the status of each well labeled with a
in eachwell of the 96-well are shown in the excel sheet, the highlightedwell (B5) contains 118 v
of 100 animals in amixedpopulation containingworms from L1 to adult stage can be used. Usin
images froma scanned96-well plate of synchronized population of animals fed bacteria transfor
effect on animal size was already known [23,37]) for one (mild P0, parental generation) or two (
(B) using the Spotdetector BioApplication of the CellOmicsArray Scan Reader. Bar graph shows
control, t test.optimal number of animals per well to have a reliable count is b100
in a population of mixed stage animals, not to exceed 50 animals per
well if working with a population of synchronized adults. We then de-
veloped a protocol to identify smaller size adults. C. elegans develops
from egg to adult in 3 days at 20 °C through 4 larval stages (L1–L4),
which progressively grow in size. To distinguish animals in different
phases of their development or of different size, the Spot Detector can
be conﬁgured to count detected objects in each well based on different
morphological parameters. As previously shown by Gosai et al. [10], we
could quantify the number of detected objects based on their area
(not shown). Notably, the Spot Detector can correctly select objects
within, and exclude objects without, pre-selected size parameters. Of
relevance for our screening purposes, animals left untreated or treated
with two doses of RNAi against different nuclear-encoded mitochon-
drial proteins were used to establish two different size cut-offs: the
ﬁrst was ﬁxed to identify objects bigger than 300 pixels while the
second was to identify objects smaller than 150 pixels (Fig. 2B). We
obtained almost identical, and highly reproducible results, using mild
and strong RNAi against nuo-2 (coding for the C. elegans ortholog of
the NDUFS3 subunit of mitochondrial complex I), spg-7 (coding for a
metalloprotease orthologous of human paraplegin), or other MRC
complexes such as complex III (isp-1 RNAi) or complex V (atp-3 RNAi)
(not shown), already known to lead to discrete animal phenotypes
[23,24,27,37,38]. This ﬁnding allowed us to distribute detected objects
in three different categories of size as surrogate markers for different
degrees of mitochondrial stress: (i) objects N 300 pixels = no mito-
chondria stress; (ii) 150 pixels ≤ objects ≤ 300 pixels =mild mitochon-
drial stress; (iii) objects b 150 pixels = severe mitochondrial stress.from the live scan panel of the SpotDetector BioApplication using a 1.25× objective. In the
le the ones labeled in orange are those rejected and therefore excluded from the analysis.
colour and the corresponding colour legend on the left. The number of animals identiﬁed
alid objects. Using the SpotDetector BioApplication and a 1.25×magniﬁcation amaximum
g a population of only adults it is preferable to have ≤50 animals perwell.B)Representative
medwith empty vector (control) orwith either one of twodsRNA (nuo-2 and spg-7, whose
strong F1, ﬁrst ﬁlial generation) generations. C) Size quantiﬁcation of animals treated as in
mean± SEM. * p value b 0.05, **p value b 0.01, ***p value b 0.005; **** p value b 0.0001 vs
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that primarily reduce animal size between 300 pixels and 150 pixels
as a ﬁrst indication for those acting through mild mitochondrial stress,
and therefore with potential pro-longevity activity.Finally, the Spot Detector can also be exploited to quantify intensity
and distribution of ﬂuorescently tagged proteins in transgenic animals.
It can detect and quantitate ﬂuorescence as total ﬂuorescence intensity
per object, total spot numbers or total spot area per object [10]. We
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genic animals and had to establish different protocols with different
threshold parameters depending on the strain (Fig. 3A, B). For the pur-
pose of our screening, we elected to monitor the expression of two
stress reporter genes, the glutathione S-transferase 4 (gst-4) and the
heat shock protein 6 (hsp-6), whose induction is typically associated
with, although not necessarily correlated or causally involved in,
lifespan-extension upon genetic or pharmacological inhibitors of
the MRC [24,36,39–44]. Similar to many other mitochondrial proteins
partial suppression of spg-7 extends lifespan, reduces animal size, and
induces the expression of the gst-4 and of hsp-6 over that of the control
animals: we could clearly distinguish untreated animals from those
treated with mild or strong spg-7 RNAi by quantifying animal ﬂuores-
cent intensity using the ﬂuorescent channel (Fig. 3C–H). We validated
the automated analysis by comparing the intensity of the signal ob-
served in the reporter strain using a ﬂuorescent stereomicroscope
and quantiﬁed manually with the ImageJ software (Fig. 3D, G), with
the GFP intensity automatically measured by the Spot Detector Bio-
Application (Fig. 3E, H), and obtained comparable measurements. The
induction of these reporter genes can be therefore used along with
sizemeasurement as an additional and early automatically quantiﬁable
indicator of mitochondrial stress.
2.2. Validation with life-extending mitochondrial-targeting drugs
Once protocols to discriminate animal size and ﬂuorescent intensity
using genetic interventionswere optimized, we tested pharmacological
interventions modulating mitochondrial function. Speciﬁcally, we
employed paraquat, rotenone, doxycycline and oligomycin, which at
discrete concentrations were previously shown to extend lifespan in
C. elegans [45–48]. Paraquat generates superoxides in mitochondria by
redox cycling and signiﬁcantly extends C. elegans lifespan only when
used at low concentrations (0.125–1mM) [49]; Rotenone is an inhibitor
of complex I of theMRCandwhenadministered after larval development
at 100 nM, extends C. elegans lifespan [45]; Doxycycline is an inhibitor of
mitochondrial translation, thus blocking MRC biogenesis, and extends
lifespan of the nematode at concentration ranging from 15 μg/ml
(29.2 mM) up to 60 μg/ml (116.9 mM) [46]; and Oligomycin is a potent
inhibitor of themitochondrial ATPase, whose treatment beginning at the
young adult stage (40 μM), extendedwild-type wormsmean lifespan by
32.3% [47]. We assessed whether, similar to discrete doses of dsRNA
against different MRC proteins, there were drug concentrations that,
when fed continuously from embryos through animal development,
mimicked the effects of mild versus severe mitochondrial stress. Using
the two reporter strainsmentioned above,we examined animal develop-
ment, size, fertility and GFP expression, as surrogate for mitochondrial
stress, and tested the four chemicals at concentrations ranging from
nM tomM looking for two doses whichmatched the screening's criteria:
a lower dose, which reduced size, fertility and induced the transgenes,
and a higher dose, which arrested animals development at a larval
stage (L2/L3) and differentially affected transgenes expression. The effect
of rotenone and oligomycin on size and fertility was slightly less pro-
nounced on the gst-4::gfp reporter strain compared to the hsp-6::gfp
strain. Nonetheless, for all of these mitochondrial-targeting drugs, we
identiﬁed two concentrations that produced a mild and a strong pheno-
type (Figs. 4 and 5) thus validating the screening criteria. The life-Fig. 3. Optimized protocols for ﬂuorescent transgenes quantiﬁcation. A) Representative con
ing gst-4::GFP animals grown for three generations on bacteria expressing dsRNA against frh-1
proteins of the MRC). The protocol was designed to identify and validate objects based on size
jective. The scanning time for the ﬂuorescent channel was in average 20min for a 96-well plate
the animals are distributed based on their average intensity in the whole body. Images of the s
Average ﬂuorescence intensity (y-axis) represents the ﬂuorescent intensity of each single id
how many objects (1, 2, 3…) are identiﬁed with the different ﬂuorescence intensity. C and F)
empty vector (control) or with dsRNA against spg-7mild (P0, parental generation) or strong (F1
with a Leica MZ10F modular stereomicroscope, 32× magniﬁcation, connected to a color digital c
gov/ij/) (D and G) or with the SpotDetector BioApplication (E and H). Bar graphs represent mean
t test.extending effect of oligomycin was so far only tested in adults [47]. We
therefore assessed whether, similar to the other drugs, oligomycin could
also extend lifespan when animals are treated from hatchlings with the
mild concentration identiﬁed in our assay. As expected by a typical mild
mitochondrial stresswe found that oligomycin 2Msigniﬁcantly extended
wild-type C. elegans lifespan compared to untreated animals (Figure S1A,
Table 1) thus conﬁrming the validity of our screening criteria regardless of
the strain background. In further support of the validity of our screening
criteria, a similar size-based readoutwas recently utilized (not for screen-
ing purpose), to conﬁrm at the organismal level new mitochondrial
modulators identiﬁed through a mammalian cells-based screening of
FDA-approved drugs [50].
2.3. Identiﬁcation of a new mitochondrial targeting molecule with
pro-longevity effect
Finally, we tested whether recently developed ATPase modulators
with anti-inﬂammatory properties [25], matched our screening criteria
and extended animal lifespan. For these studies, we used LYC-30904,
which, similar to other molecules of the same chemical series but with
increased potency, binds to the oligomycin sensitivity conferring pro-
tein (OSCP) of the mitochondrial F1F0-ATPase [51,52] (Figure S2A). 50
C. elegans L1 larvae of the hsp-6::GFP transgenic strain were dispensed
in triplicate in NGM plates supplemented with DMSO or LYC-30904
at four different concentrations (0.1–1–10–100 μM) and the effects
on animal viability, fertility, development, and GFP induction were ob-
served for up to three days (when untreated worms reached the ﬁrst
day of adulthood). Animals were then manually transferred into 96
wells and the plate was automatically screened with the Cellomics
ArrayScan using a ﬂuorescence ﬁlter to identify those giving the pheno-
typic alteration in size, fertility and expression of stress response gene.
LYC-30904 at 10 μM slightly but signiﬁcantly reduced animals' adult
size and altered the fertility whereas at 100 μMarrestedworm develop-
ment (Fig. 6A–B). Moreover LYC-30904 at 10 μM activated the expres-
sion of the stress response genes hsp-6 (Fig. 6C) and gst-4 (Fig. 6D).
As a control LYC-30930, a compound of the same chemical series that
is more than 50 fold less active than LYC-30904, did not induce any
signiﬁcant change in animal size or transgene induction not even at
the highest concentration (Figure S2B). Given that the molecule
matched our screening criteria we then assessed mitochondrial func-
tional parameters in whole extracts of animals after three days of treat-
ment with the drug. Similar to the effect of ATPase modulators in
mammalian cells [53], LYC-30904 treatment did not reduce total ATP
concentration and increased ROS levels (Fig. 6E, F), the latter consistent
with the elevated induction of the antioxidant gst-4, thus conﬁrming
that 10 μMis a dose atwhich LYC-30904 is active in C. elegans. To further
characterize the effect of LYC-30904, we then quantiﬁed the number of
eggs laid during the entire fertile period. We did not observe a signiﬁ-
cant difference between control and treated worms (Fig. 6G). However,
the daily fertility rate and the fertile period were signiﬁcantly affected:
in the 3rd and 4th fertile days untreated animals laid more than double
the amount of eggs compared to the worms treated with LYC-30904,
but during the next days these animals kept laying eggs while control
animals had stopped two days earlier (Fig. 6H). These data are consis-
tentwith the reduced fertility rate but prolonged fertile period associated
with pro-longevity genetic interventions affecting mitochondrialtrol panel of the Spot Detector BioApplication during a live-scan of a 96-well plate contain-
(the C. elegans homolog of human frataxin, involved in the biogenesis of iron-sulfur cluster
and to quantify the GFP intensity using the same channel with a 1.25× magniﬁcation ob-
. B) Each singleworm identiﬁed as valid object in the live-scan is plotted on a graphwhere
ingle worms are shown on the right. Each point on the graph corresponds to one animal.
entiﬁed object automatically adjusted based on its area. Object number (x-axis) indicates
Representative pictures of hsp-6::GFP reporter strain fed bacteria transformed either with
, ﬁrst generation, arrested animals). Pictures were acquired, when animals were 3 days old,
amera 0.5×. GFP signal from these animals was quantiﬁed with Image J (http://imagej.nih.
± SEM. * p value b 0.05, **p value b 0.01, ***p value b 0.005; **** p value b 0.0001 vs control,
Fig. 4. Validation of protocol using mitochondrial-targeting drugs on the gst-4::GFP reporter strain. Identiﬁcation of “mild” and “strong” concentrations of mitochondrial-targeting
drugs using the established size criteria on the gst-4::GFP reporter strain. Animals were treated with DMSO 0.1% (control column), or with the indicated concentrations of drugs,
which lead to smaller size and reduced fertility (mild column) or to development arrest (strong column) and therefore matching our screening criteria. 4-day old animals are shown.
The induction of the gst-4was not quantitatively assessed but an estimation of its induction was made observing the animals with a Leica MZ10F modular stereomicroscope and the ap-
propriate ﬂuorescence ﬁlter and rated with +, ++, +++ or ++++when proportionally induced (or with a—when reduced) compared to control.
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10 μM would increase C. elegans lifespan. Indeed LYC-30904 at 10 μM
not only extended animal fertile period but it also signiﬁcantly prolonged
C. elegans lifespan (Fig. 6I, Table 1), thus providing the proof of principle
that our screening strategy can be used to identify interventions that pro-
mote longevity in a multicellular organism. Of note, the overall increase
in absolute life length mediated by LYC-30904 is not due to extension
of larval development but to lifespan extension of the adult phase
(Figure S1B, Table 1). Indeed, LYC-30904 10 μM did not affect the devel-
opment of the animals, which reached adulthood and began laying eggs
on the same day of untreated animals, although at a different rate
(Fig. 6H). On the contrary, we found that LYC-30904 10 μM treatment
only during adulthood does not extend animals' lifespan (Figure S1C,
Table 1). Interestingly, this is consistent with the notion that mitochon-
drial function has to be reprogrammed during development to achieve
the lifespan extending effect [23,28].
3. Discussion and conclusions
The utilization of dietary and pharmacological factors coupled
with the use of invertebrate animals as model organisms to delay age-
associated detrimental changes, is a promising strategy that has at-
tracted signiﬁcant interest. However, the lack of speciﬁc markers for
healthy aging, which can be reliably and concurrently quantiﬁedthrough automated platforms, represents a limitation of current screen-
ing strategies and is a major bottleneck in the development of fast, less
costly and unbiased screenings. Attempts to automatically quantify
phenotypic traits associated with aging have been made, using the
Worm Microtracker machine [54] and more recently the WormFarm
microﬂuidic device [20], for long-term recordings of C. elegansmotility.
Early biomarkers of healthy agingwere nevertheless still missing so far.
Here, taking advantage of the early and well distinct C. elegans pheno-
types associated with different levels of mitochondrial stress we estab-
lished a new in vivo, high-content automated microscopy strategy,
which can now be exploited to search for candidate compounds or
small molecules promoting healthy-aging.
C. elegans short lifespan has been exploited for high-throughput
genetic and pharmacological screening in search of pro-longevity inter-
ventions. However, lifespan assays in liquid or solid media require
speciﬁc culturing conditions (possibility to separate the population
under study from the next generation or sterility, proper food amount,
large amount of chemicals etc.) that need to be maintained for a long
period of time (up to four weeks), which eventually limits their use.
Here we used surrogate markers of healthy aging to implement screen-
ing strategies for anti-aging compounds. We optimized our workﬂow
by modulating the potency of the RNA-interference against mitochon-
drial proteins, which we had previously shown to be associated with
distinct phenotypic readouts and lifespan outcomes [23,24,27,36].
Fig. 5. Validation of protocol using mitochondrial-targeting drugs on the hsp-6::GFP reporter strain. Identiﬁcation of “mild” and “strong” concentrations of mitochondrial-targeting
drugs using the established size criteria on the hsp-6::GFP reporter strain. Animals were treated with DMSO 0.1% (control column), or with the indicated concentrations of drugs, which
lead to smaller size and reduced fertility (mild column) or to development arrest (strong column) and thereforematching our screening criteria. 4-day old animals are shown. The induc-
tion of the hsp-6was not quantitatively assessed but an estimation of its induction was made observing the animals with a Leica MZ10F modular stereomicroscope and the appropriate
ﬂuorescence ﬁlter and rated with +, ++, +++ or ++++when proportionally induced compared to control.
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duce C. elegans adults' size and fertility, which are phenotypes typically
observable in three days, compared to four weeks for lifespan. Consis-
tently, we found that classical mitochondrial-targeting drugs such as
rotenone or doxycycline, known to extend C. elegans lifespan also re-
duced animal size and fertility at speciﬁc concentrations. A small pilot
screening with additional mitochondrial modulators is currently on-
going to verify the suitability (in terms of statistical signiﬁcance) of
our strategy for larger screenings. The possibility of exploiting in vivo
strategies with reliable and early readouts will allow fast screening
and identiﬁcation of bioactive molecules and recognition of toxic orTable 1
Lifespan summary statistics.
Strain Treatment Mean lifespan ± SEM (day
Wild-type (N2) Control (DMSO 0.1%) 20.77 ± 0.43
LYC-30904 10 μM (from eggs) 23.19 ± 0.45
Wild-type (N2) Control (DMSO 0.1%) 20.19 ± 0.36
LYC-30904 10 μM (from adulthood) 20.09 ± 0.36
Wild-type (N2) Control (DMSO 0.1%) 19.32 ± 0.43
Oligomycin 2 μM 21.34 ± 0.44
a % increase mean lifespan compared to control.
b Kaplan–Meier survival analysis, Log-rank test against control.
c Pooled worms from n replicate experiments (censored individuals were included in the anineffective compounds. The use of animal size as a surrogate marker
for healthy aging may also, however, lead to the identiﬁcation of false
positives: interventions eliciting Mit mutants' phenotypic features
possibly through the indirect activation of the same mitochondrial
stress response pathways, without directly targeting mitochondria or
without extending lifespan. A validation phasewill nonetheless conﬁrm
whether identiﬁed interventions actually affect mitochondrial function
and most importantly, whether these extend healthy lifespan.
In further support of the validity of our screening strategy, recent
work identiﬁed mitochondrial modulators by screening FDA-approved
drugs in mammalian cells, which were then shown to reduce size ands) Lifespan change (%)a P value vs controlb Sample size (censored)/
n trialsc
160(43)/2
+11.65 0.0002 160(49)/2
160(56)/2
−0.49 0.8516 154(37)/2
160(58)/2
+10.45 0.0030 160(40)/2
alysis until the day they were censored).
Fig. 6. Identiﬁcation of LYC-30904 as newmitochondrial targetingmolecules with life-extending ability. A) Representative images showing size alterations in hsp-6::GFP transgenic
animals after 4 days of treatmentwith DMSO0.1% (control) orwith LYC-30904 10 or 100 μM. Pictures are takenwith a LeicaMZ10Fmodular stereomicroscope, 32×magniﬁcation.B) Size
quantiﬁcation of hsp-6::GFP transgenic animals treated as in (A). Data are represented as mean number of pixel ± SEM (control = 332.6 ± 6.8; LYC-30904 10 μM= 286.2 ± 6.7; LYC-
30904 100 μM= 63.9 ± 10.9) (n = 190). C) hsp-6 induction quantiﬁed with the Spot Detector BioApplication in hsp-6::GFP reporter strain treated as in (A). The GFP induction upon
mild and severe molecule concentrations are normalized against staged matched control animals. D) gst-4 induction quantiﬁed in 4-day old adult animals with the Spot Detector
BioApplication using gst-4::GFP reporter strain treated with DMSO 0.1% (control) or with LYC-30904 10 μM. E–F) ATP and ROS levels in wild-type animals treated for 3 days as in (D).
G–H) Eggs laid in the entire fertile period or per day per worm bywild-type animals treated as in (D). I) Survival analysis of wild-type animals treated as in (D). See Table 1 for summary
statistics from Kaplan–Meier survival analysis. Bar graphs represent mean ± SEM. * p value b 0.05, **p value b 0.01, ***p value b 0.005; **** p value b 0.0001 vs control, t test.
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shown to extend C. elegans lifespan, often through a dose–response
hormetic mechanism similar to mitochondrial stress [55,56]. In many
cases, these interventions do not have a clear intracellular target or func-
tion and it will be interesting to test them in our screening platform for
possible mitochondrial activity. On the other hand, many chemicals or
toxicants directly affect mitochondrial function [57] and it will be inter-
esting to test them in our platform and eventually in survival assays to
check whether, consistent with the mitohormetic phenomenon, they
may display pro-longevity effects at any concentration. Noteworthy,
we further validated the use of animal size as a surrogate marker for
healthy aging as a strategy to identify small molecules that target
mitochondria and extend lifespan by using small molecules that targetmitochondria and for which an effect on C. elegans lifespan was not
known. We found that an allosteric modulator of the mitochondrial
F1F0-ATPase reduced animal size and fertility and induced the ex-
pression of stress response genes at low dose (10 μM) while arresting
animal development at higher dose (100 μM). Importantly the same
concentration (10 μM) that reduced size and fertility had a pro-
longevity effect, thus conﬁrming the predictive value of size and fertility
as biomarker for healthy aging. Further studies will be necessary to
establish whether our readouts can be used as a surrogate marker also
for interventions extending C. elegans lifespan independent of their
activity on mitochondria.
Finally, live animal screens are also ideal to search for suppres-
sors (rather than inducers) of speciﬁc phenotypes. In the context of
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(HMADs) [24,58], our screening platform could be exploited to search
for suppressors of the disease-relevant phenotype (i.e. developmental
arrest or sterility) resulting from severe deﬁciency of themitochondrial
diseases-associated C. elegans homologs (e.g. frataxin, paraplegin). Our
previous ﬁndings indicate that genetic manipulations can rescue the
arrest development of animals upon severe mitochondrial stress [36]
thus envisioning the possibility of identifying either targeted or un-
biased pharmacological interventions for the treatment of the corre-
sponding human diseases. In summary, we described a new approach
that can lead to the development of screenings aimed at identifying
on the one hand diseases-phenotype suppressors, and on the other
hand compounds inducing the typical Mit mutants' phenotypes and
thus potentially promoting healthy aging.
4. Materials and methods
4.1. C. elegans strains and maintenance
We employed standard nematode culture conditions [59]. All strains
weremaintained at 20 °ConNematodeGrowthMedia agar supplemented
with Escherichia coli (OP50 or transformed HT115). Strains employed in
this work were as follows: N2 (wild-type), SJ4100 (zcIs13[hsp-6::GFP])
and CL2166 (dvIs19[pAF15(gst-4::GFP::NLS)] III).
4.2. RNAi feeding
The following dsRNA transformed bacteria for feeding were derived
from the Ahringer C. elegans RNAi library [60]: nuo-2 (T10E9.7), spg-7
(Y47G6A.10). Feeding RNAi construct against frh-1 has been previously
described [23,27]. All dsRNA bacterial clones were grown overnight and
the ﬁnal concentration was adjusted at 0.9 OD dilutingwith empty vec-
tor expressing bacteria as previously described [23].
4.3. Drug assays
Chemicals used in thisworkwere all acquired fromSigma: Rotenone
(R8875), Paraquat (36541), Doxycycline (1822) and Oligomycine
(75351). LYC-30904 and LYC-30930 were provided by Lycera Corpora-
tion (Ann Arbor, US). Treatments of C. eleganswere carried out on NGM
agar plates containing themitochondrial targeting drugs. All agar plates
were prepared from the same batch of NGM agar, whereas treatment
plates were supplemented with the respective compound and control
plates with the respective solvent. Drug treatment was performed using
UV killed bacteria (HTT115) to avoid interference by the xenobiotic-
metabolizing activity of Escherichia coli. Drugs have been spotted on the
dried bacteria layer. Distillatedwater or DMSOwas used as solvent (max-
imum DMSO concentration used was 0.1%). After spotting plates were
dried overnight at room temperature and used the day after.
4.4. Multiwell plates preparation for screening
On the day of the screen, assay NGM plates containing the animals
under treatment (2 × 6 cm plates per condition) were washed with S-
medium. Animals washed off were transferred into 15 ml conical
tubes and allowed to settle by gravity for 5 min. After discarding the
supernatant, animals were washed again with 5 ml of S-medium to
remove excess bacteria and other debris that could interfere with
worm imaging. Aliquots of 150 μl of suspension were then transferred
in each well of a 96 well plate. Prior to imaging, worms were anesthe-
tized by adding 2 μl of 1 M NaN3 in S-medium to each well and the
plate closed with a clear sealing ﬁlm. Images were acquired with the
ArrayScan VTI HCS Reader ﬁtted with a 2.5× objective and a 0.63×
coupler using a 1-channel (GFP) assay. Real-time analysis was per-
formed using the Spot Detector BioApplication optimized to quantifyﬂuorescent protein expression in C. elegans. Image acquisition and
analysis of a 96-well plate were completed in b25 min.
4.5. Quantiﬁcation of in vitro ATP and ROS content
Adenosine triphosphate (ATP) and reactive oxygen species (ROS)
measurements were performed using protocols described elsewhere
[61]. Populations of ~1000 synchronized young adult animals were
collected in S-basal, washed twice, immediately frozen in liquid. Frozen
worms were then thawed in ice and mixed with S-Basal plus inhibitor
cocktail (Roche 11836170001) in a ﬁnale volume of 200 μl. Zirconia
beads (1.0 mm, Biospec Products) were added to make a ~50% (vol/
vol) slurry and the sample was bead beaten (Tissue Lyser II-Qiagen)
for 2 times for 2 min (1 min in ice between the two cycles) at room
temperature. The lysate was then centrifuged for 10 min at 14,000 g at
room temperature. A Bradford assaywas performed on the supernatant
to quantify the protein extract. ATP contentwas immediatelymeasured,
in duplicate from each biological sample, in an Inﬁnite 200 PRO Tecan
reader in ﬂat bottom 96-well white plates, using 25 μg of extract with
the ATP Bioluminescence Assay Kit CLS II (Roche) according to the
manufacturer's protocol. Each assay included a sample with no extract
as background. Reactive oxygen species were quantiﬁed utilizing
50 μg of extract incubated in 500 μl of a 5 μM H2-DCF-DA (2′-7′-
dichloroﬂuorescein-diacetate) solution in S-Basal plus inhibitor cocktail.
Each sample was read in triplicate (150 μl each) in ﬂat bottom 96-well
plate in an Inﬁnite 200 PRO Tecan reader at excitation/emission wave-
lengths of 485 and 528 nm. Readingswere performed over 2 h to ensure
that the reactionwas occurring as expected. ROS andATPmeasurements
were conducted on three independent biological replicates and are
presented as means ± SEM.
4.6. Characterization of fertility and brood size
L4 hermaphroditeswere individually cloned onto small (3 cm)NGM
plates spotted with 50 μl of bacteria (HTT115) at 20 °C. The hermaphro-
dites were transferred to fresh plates at 24-hour intervals. Hatched
progeny were counted after 48 h to facilitate the count of the larvae.
The brood size of each animalwas calculated as the sumof total progeny
in the all fertile period.
4.7. Lifespan assay
Survival curves and statistical analyseswere carried out as previously
described [36]. Speciﬁcally, survival analysis started from hatching and
was carried out at 20 °C using synchronous populations of 80 animals
per condition. Animals were scored as dead or alive and transferred
every day on fresh plates during the fertile period, and then every
other day or every 3 days until death. Worms are considered dead
when they stop pharyngeal pumping and responding to touch. Worms
that died because of internal bagging, desiccation due to crawling on
the edge of the plates, or gonad extrusion were scored as censored.
These animals have been included in lifespan analyses up to the point
of censorship and are weighted by half in the statistical analysis. We
calculated mean lifespan, standard deviation of the mean, and P value
(Mantel–Cox regression analysis) from Kaplan–Meyer survival curves
of pooled population of animals coming from at least two independent
replicas. For statistical analysis we used the Online Application for
Survival analysis OASIS [62]. All data from survival analysis are summa-
rized in Table 1.
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